10 Most Promising Cancer Stocks According to Hedge Funds

5. Kura Oncology, Inc. (NASDAQ:KURA)

Average Analyst Upside: 63.27%

Number of Hedge Fund Holders: 36

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer treatment, with a particular emphasis on small-molecule inhibitors that target specific genetic and epigenetic abnormalities in cancer cells.

H.C. Wainwright recently reaffirmed its Buy rating for Kura Oncology shares, setting a price target of $32. The firm’s analyst highlighted the potential of Kura’s menin inhibitor, ziftomenib, in treating advanced gastrointestinal stromal tumors (GIST). At the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, preclinical data demonstrated promising results for ziftomenib in this application. Kura Oncology, Inc. (NASDAQ:KURA) plans to initiate a Phase 1 clinical trial in the first half of 2025 to evaluate ziftomenib in combination with imatinib, a KIT inhibitor, for patients with advanced GIST. The company has already received IND clearance, allowing it to proceed with human trials.

Looking forward, Kura Oncology, Inc. (NASDAQ:KURA) anticipates significant milestones, including the presentation of updated data at the American Society of Hematology Annual Meeting in December 2024 and the launch of new studies in early 2025. Management remains optimistic about the potential of its menin inhibitor programs and broader pipeline, advancing its mission in precision oncology.